Creabilis Itching To Start Phase III Tests Of Lead Asset For Chronic Pruritus
This article was originally published in Scrip
Keen to make up for lost time, dermatology specialist Creabilis Ltd is using positive Phase IIb data to advance its lead anti-itch product CT327, a novel topical TrkA kinase inhibitor, on to Phase III trials in psoriasis patients which, if successful, should open the way for regulatory filing in mid-2018 for a condition where there is no approved standard of care.
You may also be interested in...
Creabilis has finally secured the future of its Phase III-ready psoriatic itch candidate CT327 – through a sale of the company to young US firm Sienna Biopharmaceuticals.
Regeneron Pharmaceuticals Inc. reported statistically significant pain relief for osteoarthritis sufferers enrolled in the company's Phase II/III clinical trial for fasinumab, but the data didn't relieve concerns about neuro-musculoskeletal side effects for medicines that inhibit nerve growth factor (NGF).
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.